A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy
Steinberg, Gary D., Palou-Redorta, Joan, Gschwend, Juergen E., Tran, Ben, Loriot, Yohann, Daneshmand, Siamak, Roupret, Morgan, Santiago-Walker, Ademi E., Switzky, Julie C., Major, Christopher, Baig, Mahadi, Xia, Qi, Catto, James WF
Published in Journal of clinical oncology (20.02.2020)
Published in Journal of clinical oncology (20.02.2020)
Get full text
Journal Article
A phase 1b/2 study of INCB039110 + nab-paclitaxel (N) and gemcitabine (G) in patients (pts) with advanced solid tumors and pancreatic cancer (PC)
Beatty, Gregory Lawrence, Shahda, Safi, Beck, J. Thaddeus, Uppal, Nikhil Premparkash, Cohen, Steven J., Donehower, Ross C., Gabayan, A. Eli, Assad, Albert, Switzky, Julie C., Zhen, Huiling, Von Hoff, Daniel D.
Published in Journal of clinical oncology (01.02.2017)
Published in Journal of clinical oncology (01.02.2017)
Get full text
Journal Article
Efficacy/safety analysis of a phase 2 study of ruxolitinib (Rux) + regorafenib (Re) in patients (pts) with relapsed/refractory (r/r) metastatic colorectal cancer (mCRC)
Fogelman, David R., Bendell, Johanna C., Cubillo, Antonio, Garcia Alfonso, Pilar, Limón Mirón, María Luisa, Nemunaitis, John J., Flora, Daniel Blake, Borg, Christophe, Mineur, Laurent, Vieitez, Jose M, Cohn, Allen Lee, Saylors, Gene Brian, Assad, Albert, Switzky, Julie C., O'Neill, Peter, Zhou, Li, Kochenderfer, Mark D.
Published in Journal of clinical oncology (01.02.2017)
Published in Journal of clinical oncology (01.02.2017)
Get full text
Journal Article
Phase II study of ruxolitinib with regorafenib for relapsed/refractory (r/r) metastatic colorectal cancer (mCRC)
Fogelman, David R., Kochenderfer, Mark D., Saylors, Gene Brian, Braiteh, Fadi S., Nemunaitis, John J., Cohn, Allen Lee, O'Neill, Peter, Zhou, Li, Switzky, Julie C., Assad, Albert, Bendell, Johanna C.
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia
Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S
Published in Blood (18.11.2011)
Published in Blood (18.11.2011)
Get full text
Journal Article
BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets)
Kirkwood, John M., Long, Georgina V., Trefzer, Uwe, Davies, Michael A., Ascierto, Paolo Antonio, Chapman, Paul B., Puzanov, Igor, Hauschild, Axel, Robert, Caroline, Kefford, Richard, Goodman, Vicki L., Switzky, Julie C., Swann, R. Suzanne, Martin, Anne-Marie, Guckert, Mary E., Streit, Michael R. W., Schadendorf, Dirk
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article
A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia
Furman, Richard R., Eradat, Herbert, Switzky, Julie C., Hayman, Suzanne R., Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Liao, Qiming, Shah, Damini N., Brownell-Buttich, Stephanie, Lisby, Steen, Lin, Thomas S.
Published in Blood (19.11.2010)
Published in Blood (19.11.2010)
Get full text
Journal Article